NCT06623422 — intismeran autogene (mRNA-4157) neoantigen vaccine trial
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Registry record
| Registry ID | NCT06623422 ↗ |
|---|---|
| Lead sponsor | Merck Sharp & Dohme LLC |
| Collaborators | ModernaTX, Inc. |
| Phase | Phase 3 |
| Status | Recruiting |
| Indication | Carcinoma, Non-Small-Cell Lung |
| Enrollment | 680 participants (target) |
| Start date | 2024-10-21 |
| Primary completion | 2033-05-16 (est.) |
| Last registry update | 27 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06623422), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06623422?
NCT06623422 (A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)) is registered on ClinicalTrials.gov as Phase 3, sponsored by Merck Sharp & Dohme LLC.
Is NCT06623422 recruiting?
As of the 2026-08-27 registry update, NCT06623422 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06623422?
The lead sponsor is Merck Sharp & Dohme LLC. Collaborators: ModernaTX, Inc..
What condition does NCT06623422 study?
The registered condition is Carcinoma, Non-Small-Cell Lung. Primary completion is listed as 2033-05-16 (estimated).
Are results available for NCT06623422?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06623422.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.